! " # $%&% '
-
1! "
-
2$ " %&'
3
) *+
! " ! #$! % &'
:()
!
*+
.
! - . / 0!
1 2(3 45 6 -'7 ! * 8
9 '7)' :;
0<
= ' 4 '
' > 1 ' 1 ? ! 4 = ' @ & ? (A' B
1 2(3 45 6 9 8
C + 9 '
!
* . / 0!
1 D* E A 1 2(3 -'7 ! = '
8 :;
-F = ' 1 GH
0< %!' 1 2 ; I / > &'
/ JK
*+* 3 ' 1 ;
(ox-LDL)
+ 8 L '
* .
1 '
:! / 0!
-
* + 260
* *+ / 0! ' *G(+' )' Q F & ' )' &' R .
%! + ! Q
130 R U " @ % '*A J() Q 50
% Q
* + 130 R
)' Q F J() Q - *
* . -'7 !
1 2(3 8
? (3 1 2 ; I / * 3 Q
/ JK
(HDL)
U
*A' &
1 2 ; I /
HDL/ JK
(LDL)
#
ox-LDL
&'* ' Q
* Q . ' 8 &' R( '
SPSS
'7)' - !&F X G! !F G ! Y0
' 05 /
P<
0 7L
* *+ % [ .
1 2(3 -'7 !
:8
-'
mol/L
) 20 /
± 8 25 / 19 ( G ! `
&' ( '
* + Q
mol/L
) 17 /
± 4 8 / 14 ( B JG :( ! -' 1 GH G ! 4 a! = '
9 '7)' 1 ' Y0
8 1 2(3
ox-LDL
Y0 :;
*+ * ! )
426 / 0
r
= 001 /
P<
0 (.
>
HDL2
9 :( ! -' JG
* + Q 4 3 9 1 2(3 Y0 9 '7)' 1 $> % = '
HDL2
/ 0! 1 '
*
* .
(< G+ .' c' G
:*+
9 '7)' 1 2(3 :; Y0
ox-LDL
7
! -' G * '
%!
9 '7)'
0<
d 0!
+ . B
:1 2(3
HDL
B
ox-LDL
B
. 1388 % 16 ) 3 :(
47 - 53
-. "
: 2 / 2 / 1386
" 1 234 : 9 / 7 / 1387 6 "7 : 27 / 7 / 1387
B? e3! *G3 1
+ PhD
$+ +7; 8 J ' / / ! / . f f[ 7 !
g F :
$+
- ( A - +7; * ' -
/ . f f[ 7 ! / / !
1R : 09132800382 :
3346692 0381- ( /' 43;
kgsamani@hotmail.com:
( '2
Q +& !F X +7; * ' +7; 8 J '
$+
+ *+ ' g G+ 3
/ . f f[ 7 !
! / / ' +7; 8 J
$+
)
@
& A #$! %i !
! 4!:
4 ' () .
' X i <
* ' *$
! *3!
1 ' * Q j +
C 1
! X
*+
) 1 .(
- + '*3 '
F X 6' '
&
! C +
1k 4 E 1 ' Q
? (3 J ' ! / . E * / # 3
! *G 4) % l ' <' U
*l+
! & l ' F m:; -F
*G Q .
0< %!' R (n!
G !
* J/' U - < )
*G ! k 0! < * I / 1 ; HDL
LDL
-* J U * 3 Q
L '
* ' 9f .
&' 0< %!'
#$!
! - < 1 2(3 -'7 !
*+
.
* ' @ 1 2(3
* ' #3 / (! - > 4 ' ' Q Q G !F G !F
! (< ? 1 (! E +
) 1 (.
G+ *
@ -' G 1 2(3
%!
0<
'
? 1964
*+ C + .
? -F
Mudd
' 9 - < 1 2(3 j L * ' -
4
& (G ( 1 (3 # 7 F of
(CBS)
2!
*+
! 4 $ LG
j) 1 (3
' ' p ` &'
! Q ) 2 .(
. / 0!
McCully
- of -' '
X F K CBS
! * *+
* Q qU (A'
3! -F . f( ! &' 1 2(3 e
X F ?
!
*+
) 3 ( B E ) g ' 1 ' 1 ' G ! *+ '
@ 4 ' 1 ! - < 1 2(3 9 '7)' 0< %!
' %f(3!
L '
*+ & ' F )
4 .(
' E ) 1 '
r 1 / '
Wilcken
' - * Q 9 !&F
*+
Atherosclerosis1 2
:( ! -' ' )' 4 3
* +
* ' 1 2(3 ` 6 #3 / (!
) 5 .(
. / 0!
' - s (n!
1 2(3 45 6 9 '7)' 8
*GK
? A !
c' ? * F
! 'tQ . X F
?
? ) ? * F 4 :; -*+
? ) 1 2 ; -*+
? ) C
9 '7)' () ( ) -*+
-*+ * 3 '
<
<
* LDL
!
$ F p ` &' *G+
! 1 2(3 Q & ! & ' F u * '
) 6 - 8 (.
! ( v 0 [! %!' '
*G '7)' u 9
! -'7
* Q 8 1 2(3 .
9 1 ! (
B
6@ / )* '
4 ' ' :; 1 2(3 Y0 9 '7)'
) 10 9 ( B
*+ w '7Q 1 GH 1 ! ( - 7)' 4 '
B
6B
12* ' 4) ; 9 u 't6 @ / ) j !
*+
m:;
* 101
! :(
(+' U 1 2(3 Y0
* ' +
* 4 ' ) 11 .(
&' 0 [! %!'
J $ D x!
4 E
5 G /
- `
4 F
* y !
* y ;
7 z*E ' D x!
C {
! ' . 3 (!
8 -' )
12 - 14 ( B 9 '7)' ? A
? 1 2(3 45 6
-' G
@ 0< %!
! d 0! '
*+
.
/ 0!
1 D* E A
1 2(3 -'7 ! = '
8
:;
|
1 2(3 c
45 6
*A' &
HDL HDL
2= ' 1 GH
(3 1 2 0< %!'
$
*+ * 3 ' LDL (ox-LDL)
3*+ 8 L ' .
, - ./
/ 0! 1 ' !
-
* +
>' ! Q*GG
-
}' 4 F - ( X J !
$+ +
3
? 1385
* )' Q F 8 L ' *G!&
'
*+ 8 L . - F w g ( ' )' &' Q
* Q 8 L ' .
> #LA r ' +
! . / 0! > !
260
*+ () Q 5 R .
)' Q F ' )'
8 L '
% '*A -'7 ! J() Q " @ % '*A ' ' *+
50 %
* F ' )' ! Q J() Q )' Q
*G(+'*
)
* *+ '* RG! 5 &'
(
*G() Q ' * + Q .
U ' )' 80
; - :( ! 1 GH ?
&' ( -'7 ! " @ J() Q ' )' - ` * y 50
% DtA / 0! &' @ / (! -' -'
+
* * . 5G!
3 - ' )' ! Q &
&' J ' )' &' '* 1 GH * + Q &' # 1
DtA ! Q
*+
*
% Q
260
!' ' R
4) .
~G> 1 %! + / 0! ! ' )' . xn ! ...
4 c
4 E t<' &' ~; * Q
! &' ( ! -'7 ! $ F
7 10
! ( / () Q (+ 4/ A * - <
*+
B
(n/ &' ~; { ):
8 4 # &' ( - < -*+
v R ( &' R( ' -F 3000
.*!
10 f
Q '*>
* 7 ) 20
- ' ' J ( >
8 L '
'*$J * . !&F
* Q .
w 8 1 2(3 Y0
'7 /' &' R( '
&'* ' 4 Q
4 + 4< 1 2(3 ) IBL
- /F (
*+ 1 .
? (3 Y0
* 3 Q
! 7 w
HDL 7 F
)'v w 1 G ' w
)
* ' 1 G ' 9G ' &' %{ A J ~ I %
@ ;
[!
r (
4 &' R( '
` !
g ; 4 + 4<
7 / F ' &' R( ' - !&F
RA1000
)
!F 4<
( 1
* Q .
LDL Y0
? (3 -'7 ! &'
* 3 Q
* Q [! & ? ! ) p ` HDL
:
LDL= Chol - (TG/5 + HDL)
&'* ' w 1 ($
' Q
*A' & 1
v R ( ' (/ ' &' R( ' HDL
! +
w / *
*A' & 1 ' 8&U 4 4[{ 7
! ' ' ' HDL
*G+
.
. R/ -' (3 w
MgCl
2w 1
? '*(!
!
*+
. 1 '
1 2 ; I / '*( ' w
Apo-B A .' • -
! ' k *G(3 LDL
* + .
&'* ' A ! 1 ' ) j ! ? (3 Y0 Q
-
HDL *G
! 8
*+
. j ! €' *L! A ! 1 ' &' ~;
4[ )
|
k c
! ' *G
u Q
!
HDL
2+ ' k ? ' A ! j ! &' +
.
! ? (3
? ' A ! ) j
HDL -' G 8
8 A ! j ! ? (3
HDL
3-' G
&'* ' Q
! + .
? ' A ! ? (3 D:(<' )
8 ( 8
HDL
3) (
'
HDL
2Y0 * ' <
) 15 .(
LDL Y0
* 3 '
! *+
R( ' '7 /' w
4 + 4< L 4 &'
&'* ' - /F DRG
*+ Q
X3A • ( * Q w '7Q U/L
) 16 .(
' )' 5G! 1 ' ' € ) { 1 G ' Q &'* ' :( ! / 0! &'
DtA +
* .
'
&' R( ' 8
!F '7)' ) SPSS
n3 5 / 11 (
!F - !&F G ! Y0
' 05 /
P< 0 7L
% [
*+
* B
‚(! 1 = ' '
7 - !&F &'
Paired Sample Correlation
* Q R( ' .
" 0 4 > ‚(!
/ 0! ! Q (< G+
? *>
1 F
*+
4 ' . -
! * ! Q
+
G ! D:(<' '
1
* ! Q +
.
!
1 J
&'* ' %!' ! 45 6 ! D' [ ' Q
*+
? *> * + ! Q 2
4 ' *+ y' ' .
ox-LDL Y0 3
? ( Q 1 2(3 8
45 6 9 '7)' * + 4 3 !
HDL
2- 9
!
* .
' ! 1 2(3 Y0 1 = '
&'* '
*+ Q 7
? *>
3
*+ ' - 4 '
.
= ' ! 8 1 2(3 Y0 * + Q
G ! ' ' B4+'* *+ ' !
! Q
!
Y0 9 1 2(3 9 '7)'
HDL
2Y0 9 '7)'
ox-LDL
G ! = '
' - '
) 001 /
P< 0 .(
! 1 -
$ %
& '(! ) *+
, - . , / 0 .
1 .
) 130 5 ( , -
) 130 5 ( / ' 789 ,
1 )
? ( 1
/
± 11 8 / 52 7
/
± 9 6 / 54 08
/ 0
* o< +
(kg/m2)0 /
± 4 9 / 26 1
/
± 4 1 / 27 64
/ 0
J )
1 / 26 (%
34 )
6 / 34 (%
45 09
/ 0
! )
60 (%
78 )
1 / 66 (%
86 13
/ 0
! 2 -
; <
/9 = > -? / 9 789 ' .
, - . ,
1 .
) 130 5 ( , -
) 130 5 ( / ' 789 ,
1 2(3
(µmol/L)17
/
± 4 82 / 14 2
/
± 8 25 /
*
19 001 / 0
* 3 Q
(mg/dL)01
/
± 111 45 / 201 6
/
± 110 9 / 201 46
/ 0
(mg/dL)
? (3 08
/
± 58 52 / 218 91
/
± 42 65 /
*
224 04 / 0
?
HDL (mg/dL)38
/
± 10 09 / 47 2
/
± 13 14 / 45 12
/ 0
LDL (mg/dL)
47
/
± 54 14 / 131 40
/
± 45 12 / 149 26
/ 0
HDL2 (mg/dL)
15
/
± 7 01 / 29 25
/
± 9 1 /
*
19 001 / 0
ox-LDL U/L
)
22 ( /
± 10 00 / 57 12
/
± 11 12 /
*
79 001 / 0
G ! !F 5 &' *
4 ' ' .
! 3 - /9 = > -? 9 = ;@ % 9-( 789 A B % , - . , / 9 .
.
, - 1
/< %B( C D / ' 789
, /< %B( C D / ' 789
,
? (3 02
/ 0 - 83
/ 0 18
/ 0 - 17
/ 0
* 3 Q 22
/ 0 - 10
/ 0 10
/ 0 45
/ 0
8
HDL02
/ 0 - 85
/ 0 08
/ 0 - 55
/ 0
06
LDL/ 0 63
/ 0 20
/ 0 13
/ 0
31
HDL2/ 0 82
/ 0 07
/ 0 -
* 001 / 0
ox-LDL
24
/ 0 07
/ 0 42
/ 0
* 001 / 0
G ! !F 5 &' * 4 ' '
.
1.2 :; 1 2(3 Y0 9 '7)'
@ -' G %!
0<
' %f(3!
*+ (< G+ & ' F 4 '
) 17 .(
/ 0!
E A 1 J ! Y0
1 2(3 8
!
mol/L -' 2
/
± 8 25 / 19 Q
* +
mol/L
17 /
± 4 82 / 14 .
` -'7 ! L F &'
1 2(3 8
mol/L 1 3
/ 15 - 9 / 5
!
*+
) 18 (
1 ' • ( / 0!
! - :( ! ' )' *
1 2(3 -'7 ! 8
9 '7)' ()
4 ' . 1 '
. f f[ • (
' n !
' ) 19 - 22 (.
? (3 -'7 ! 4 3 -' *+ * 3 ' LDL
4+' 9 '7)' * + Q )
05 /
P< 0 (.
- U >
Y0
LDL ? (3
~ + -*+ * 3 '
! 9 '7)' '
* ) 23 (
‚
%
$>
* + Q 4 3 4+'*
. ! 1 ' 7 * 3 Q
()
*+ * B
1 ' >
JG #y:
' )' G / G ! Q
! >
4+' 8*
>
G ! D:(<' '
Y0
* 3 Q LDL
*+ (< G+ 0< %!
*G(3 f0G!
! 5
* .
HDL
245 6
* + Q 4 3 Q
*A
33
% 4+' 9 .
1 ' / 0! ()
*+ 8 L '
' 4f 0!
) 24 .(
*GK Y0 1
HDL
1 ' / 4 ' *+ w '7Q g ! = '
3!
| G ! 1 * / Y0 ' )' 43
1 ; HDL
€ !'7/'
! :( !
* Q ) 25 (.
1 ' >
‚ 8 HDL
G ! !F 5 &' Q 1 '
! 5
‚ 1 2(3 * X
&
HDL *A'
9 u
HDL
2Y0
* Q 4 ' .
&'
HDL
2L F C' ' 4 3
(5) [! 9f HDL
( $!
'
! 5
*
45 6 9 1 2(3
HDL
2L ' ? (A'
! 9 '7)' ' & ' F
* .
3 f!
ox-LDL Y0 1
Q !
* +
/ 0! 1 ' -
'* 3 ' 9 '7)' *G
LDL - Q
4 ' . ' / 0! @ • ( g Y0 9 '7)'
* / 3! ( v of -' 1 2(3 1 (!
)
& ( .U ) * ' ( 1 (! # 7 F 5 (
ox-LDL Y0 '
! 9 '7)'
* ) 25 .(
- <' . / 0!
! G
ox-LDL * {' 9f
' / ' . E L
& ' F '
' ) 26 - 30 .(
g ' ()
) / 0!
! 5
*
1 2(3 . {
0< %!
&' % %f(3!
9 '7)' p `
ox-LDL
~ + '
! 9 '7)'
* . ( F 9 '7)'
ox-LDL *G !
7)' i - < - > 9 1 2(3 9 '
3! 1 ' 4 ' ' !
| 4 ' /
ox-LDL
3 / ' %A' ! ' 1 2(
& ' F -' > ' )'
! -
* ) 31 .(
% 9 '7)' 1 2(3 Q
- 3 ' ? ) 1 ( * /
1m:; % * / '
F
! j 3 *GG *3! . E ' 8
*G ) 32 .(
• ( g ' . / 0! 1 '
! 1 2(3 9 '7)' * '
? ) - 3 '
ox-LDL * /
* 9 '7)' ' .
E A 9 ; ' ! 1 &'
*+
! Q
G ! = ' $G '
1
! 8 1 2(3 Y0
HDL
2Y0
ox-LDL
*
*+
. 7 ( -'
ox-LDL = '
*+ ' - 1 2(3 4 '
) 33 ( B
2(3 * + Q / A 1
„
&' 8'*
%!'
> &' *+
HDL
2ox-LDL
= '
G ! 4+'* ' .
() 1 ' > -' ( * + 1 GK
-
Y0 *+ * ! 9
HDL
29 '7)' 7
ox-LDL
. c' J() Q > % / Q *+
*+ * + Q 4 3 ! B
J D ` &' > 8*
Reactive Oxygen Species1
= ' G ! !F '
1 Y0 1 2(3
ox-LDL
* + ' )' 7
% / * +
Y0 - `
1 2(3
*+ ' )' 1 ' .
7 = ' ? 1 2(3 Y0 L F &' .U ) -'7 ! D x!
B
12'
! $G ; Q
/ 0!
'
? 1 2(3 Y0
1 ! (
B
12.U )
- !' . { Q ' / 0! ! 7 - ( ' 1 '
&' 1 2(3 Y0 9 4 3 G6 p `
&
't6 # v .U )
9 4$> 8&U 8'* ' 0<
Q 8 L ' .
3 4 5 %f(3! 0< %! -' G ' 1 2(3
! d 0!
+ / 0! 1 ' /
*+ * ! 9 '7)' 1 2(3
ox-LDL Y0
GH
‚ 1
< Y0
*A' &
7 HDL
!
* ' u 9 '7)' 0<
+ .
0) /
* / + f f[ d ` %{ A / f! 1 ' 269
4 '
/ ! 4 A
; 4 !
$+ +7; 8 J '
* 8 L ' 1 *
! *f
Q .
62 :
1- Burtis CA, Ashwood ER, Brouns DE. Clinical chemistry and molecular diagnostics. 4th ed. USA: Elsevier; 2006.
2- Mudd SH, Finkelstein JD, Irrevere F, Laster L. Homocystinuria: an enzymatic defect. Science. 1964; 143: 1443- 1445.
3- McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969; 56(1): 111-128.
4- McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis.1975; 22(2): 215-227.
5- Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Investig. 1976; 57(4): 1079-1082.
6- Cobbaert C, Arentsen JC, Mulder P, Hoogerbrugge N, Lindemans J. Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine and total antioxidant status. Clin Chem. 1997; 43(10):
1958-1964.
7- Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol.1993; 22(3): 854-858.
8- Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 1998; 97(3): 237-241.
9- de Jong SC, Stehouwer CD, van den Berg M, Geurts TW, Bouter LM, Rauwerda JA. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. J Intern Med. 1999; 246(1): 87-96.
10- Vermeulen EG, Rauwerda JA, Erix P, de Jong SC, Twisk JW, Jakobs C, et al. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature atherothrombotic cerebrovascular disease. A prospective cohort study. Neth J Med. 2000; 56(4): 138-46.
11- Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens. 2000; 13(1 Pt 1): 105-110.
12- Brouwer IA, van Dusseldorp M, Thomas CM, Duran M, Hautvast JG, Eskes TK, et al. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Am J Clin Nutr. 1999; 69(1): 99- 104.
13- Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 2001; 161(5): 695-700.
14- Koehler KM, Baumgartner RN, Garry PJ, Allen RH, Stabler SP, Rimm EB. Association of folate intake and serum homocysteine in elderly persons according to vitamin supplementation and alcohol use. Am J Clin Nutr. 2001; 73(3):
628-637.
15- Roche D, Migueres ML, Lequang NT, Burstein M, Ekindjian OG, Girard-Globa A. Concentrations of high-density lipoprotein subfraction HDL2 and lipoprotein A-I in a random population of healthy subjects. Clin Chem. 1991; 37(12):
2111-2113.
16- Holvoet P, Macy E, Landeloos M, Jones D, Jenny NS, Van de Werf F, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem. 2006; 52(4): 760-764.
17- Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol. 2002; 31(1): 59-70.
18- Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med. 1999; 131(5): 331-339.
19- Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998; 5(4): 229-232.
20- Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med. 2000: 160(4): 422-434.
21- Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000; 72(2): 324-332.
22- Pezshkeyan M, Norri M, Refahi R, Afrasiabi A, Rahbani M, Qujeq D. Relationship between hyperhomocysteinemia and oxidative stress with severity of atherosclerotic lesion. J Med Sci. 2005; 5(4): 243-246.
23- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25): 3143-3421.
24- Dusti M. Isolation of HDL2 and HDL3 assessment of concentration of cholesterol. TUMJ. [serial online] 1997;
55(6): 7-12. Available from: http://journals.tums.ac.ir/abs.aspx?tums_id=5834. [Persian]
25- Schaefer EJ, Asztalos BF. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol. 2006; 17(4): 394-398.
26- Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol. 2006; 17(5): 502-509.
27- Chen J, Mehta JL. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. Curr Hypertens Rep. 2006; 8(2): 139-143.
28- Verhoye E, Langlois MR; Asklepios Investigators. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk? Clin Chem Lab Med. 2009; 47(2):128-137.
29- Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res. 2009; 50 Suppl: S376-381.
30- Young IS, McEneny J. Lipoprotein oxidation and atherosclerosis. Biochem Soc Trans. 2001; 29(Pt 2): 358-362.
31- Laaksonen R, Janatuinen T, Vesalainen R, Lehtimäki T, Elovaara I, Jaakkola O, et al. High oxidized LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults. Eur J Clin Invest. 2002; 32(11): 795-802.
32- Wang G, Mao JM, Wang X, Zhang FC. Effect of homocysteine on plaque formation and oxidative stress in patients with acute coronary syndromes. Chin Med J (Engl). 2004; 117(11): 1650-1654.
33- Koubaa N, Nakbi A, Smaoui M, Abid N, Chaaba R, Abid M, et al. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem. 2007; 40(13-14): 1007-1014.
Abstract Original Article
Evaluation of correaltion between plasma homocysteine and oxidized low-density lipoprotein in patients with coronary
artery disease
K. Ghatreh Samani1, F. Roghani2, E. Farrokhi3
Background and Aim: Cardiovascular diseases (CVD), especially coronary heart diseases (CHD) are major
causes of death in developed countries. Studies have been shown that total plasma homocysteine (tHcy) has been associated with an increased risk of CHD, probably a causal type. A lower tHcy concentration will reduce the frequency of CHD. The aim of this study was to evaluate the correlation between tHcy and CHD and its relationship with other CVD risk factors such as oxidized low density lipoprotein (ox-LDL).
Materials and Methods: A total number of 260 patients with coronary angiography indication were
included in this case control study. The study group consisted of 130 patients with at least one vessel stenosis greater than 50% and the control group consisted of 130 normal angiogram without stenosis. Total Hcy, cholesterol, triglyceride, high density lipoprotein (HDL) and its sub fractions, low density lipoprotein (LDL) and ox-LDL were measured in two groups. Data were analyzed by SPSS using relevant statistical tests at the significant level of P<0.05.
Results:
The mean serum tHcy level in CVD patients (19.25±8.20 mol/L) was significantly higher (P<0.001) than the control group (14.8±4.17 mol/L). Moreover, among patients with CVD, a positive significant correlation between tHcy and ox-LDL level in plasma, was found (r=0.426, P<0.001). Despite reduced HDL
2concentration in patients with CVD than the control group; no significant correlation between high tHcy and low HDL
2was achieved in this study.
Conclusion:
Beside other known effects, homocysteine may also act as a risk factor for cardiovascular diseases by increasing plasma ox-LDL concentration.
Key Words: Coronary heart disease; Homocysteine; HDL; ox-LDL
Journal of Birjand University of Medical Sciences. 2009; 16 (3): 47-53 Received: 21.2.2008 Last Revised: 30.9.2008 Accepted: 18.10.2008
1Corresponding Author; Cellular and Molecular Research Center, Shahrekord University of Medical Sciences kgsamani@hotmail.com.
2Assistant Professor, Cardiology Department of Medical, Shahrekord University of Medical Sciences
3
